
Seong Lin Khaw

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6742765/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nature Medicine, 2013, 19, 202-208.	30.7	2,426
2	Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease. Journal of Clinical Oncology, 2012, 30, 488-496.	1.6	719
3	Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia. Blood, 2016, 128, 1382-1395.	1.4	148
4	Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancer Discovery, 2021, 11, 1440-1453.	9.4	137
5	The Bcl-2 Homology Domain 3 Mimetic ABT-737 Targets the Apoptotic Machinery in Acute Lymphoblastic Leukemia Resulting in Synergistic in Vitro and in Vivo Interactions with Established Drugs. Molecular Pharmacology, 2010, 77, 483-494.	2.3	111
6	The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. Leukemia, 2009, 23, 2034-2041.	7.2	91
7	Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199. Leukemia, 2014, 28, 1207-1215.	7.2	79
8	Overcoming blocks in apoptosis with BH3-mimetic therapy in haematological malignancies. Pathology, 2011, 43, 525-535.	0.6	36
9	BET inhibition represses miR17-92 to drive BIM-initiated apoptosis of normal and transformed hematopoietic cells. Leukemia, 2016, 30, 1531-1541.	7.2	29
10	Safety and Efficacy of Venetoclax in Combination with Navitoclax in Adult and Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Blood, 2019, 134, 285-285.	1.4	24
11	Outcomes for Australian children with relapsed/refractory acute lymphoblastic leukaemia treated with blinatumomab. Pediatric Blood and Cancer, 2021, 68, e28922.	1.5	16
12	Venetoclax and Navitoclax in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Blood, 2018, 132, 3966-3966.	1.4	5
13	Venetoclax Alone or in Combination with Chemotherapy: Responses in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia with Heterogeneous Genomic Profiles. Blood, 2020, 136, 30-31.	1.4	4
14	SFPQ-ABL1 and BCR-ABL1 use different signaling networks to drive B-cell acute lymphoblastic leukemia. Blood Advances, 2022, 6, 2373-2387.	5.2	4
15	Two novel cases of <i>NUTM1</i> â€rearranged Bâ€cell acute lymphoblastic leukaemia presenting with highâ€risk features. British Journal of Haematology, 2022, 196, 1407-1411.	2.5	4
16	The first report of pediatric patients with solid tumors treated with venetoclax Journal of Clinical Oncology, 2020, 38, 10524-10524.	1.6	3
17	Venetoclax and Navitoclax in Pediatric Patients with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Blood, 2020, 136, 12-13.	1.4	2
18	Open-label, dose-escalation, phase 1 study of venetoclax in combination with navitoclax and chemotherapy in patients with relapsed acute lymphoblastic leukemia Journal of Clinical Oncology, 2018, 36, TPS10575-TPS10575.	1.6	1

#	Article	IF	CITATIONS
19	Cycling without brakes lets ALL escape. Blood, 2021, 138, 1912-1913.	1.4	Ο